PROM1 and neoplasm: Additionally, we detected the CSC marker CD133 in tumour tissues, and the data showed that the groups treated with MIR600HG had a significantly reduced CD133 mRNA level compared with that in the groups that were not treated with MIR600HG (Figure 7C).